ASCO: Puma Biomarker Findings from Phase II Study of Alisertib with Paclitaxel in Breast Cancer

  Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone (Clinicatrials.gov identifier NCT02187991) in metastatic hormone receptor positive (HR+) and triple negative (TN) breast cancer at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting held June 2-6 in Chicago and online. The Phase II trial was conducted through The US Oncology Network. The results of this trial were published by Joyce O’Shaughnessy et al. (Jama Network Open, April 2021) and showed that the addition of alisertib to paclitaxel improved progression-free survival (PFS) among enrolled patients compared with paclitaxel alone (HR, 0.56; 95%CI, 0.37-0.84; P = .005).

https://www.biospace.com/article/releases/puma-biotechnology-announces-presentation-of-biomarker-findings-from-a-phase-ii-study-of-alisertib-with-paclitaxel-versus-paclitaxel-alone-in-metastatic-or-locally-recurrent-breast-cancer-at-the-2023-asco-annual-meeting/